Redox Regulation of RhoA
- 9 November 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 45 (48) , 14481-14489
Abstract
We have previously shown that redox agents including superoxide anion radical and nitrogen dioxide can react with GXXXXGK(S/T)C motif-containing GTPases (i.e., Rac1, Cdc42, and RhoA) to stimulate guanine nucleotide release. We now show that the reaction of RhoA with redox agents leads to different functional consequences from that of Rac1 and Cdc42 due to the presence of an additional cysteine (GXXXCGK(S/T)C) in the RhoA redox-active motif. While reaction of redox agents with RhoA stimulates guanine nucleotide dissociation, RhoA is subsequently inactivated through formation of an intramolecular disulfide that prevents guanine nucleotide binding thereby causing RhoA inactivation. Thus, redox agents may function to downregulate RhoA activity under conditions that stimulate Rac1 and Cdc42 activity. The opposing functions of these GTPases may be due in part to their differential redox regulation. In addition, the results presented herein suggest that the platinated-chemotherapeutic agent, cisplatin, which is known for targeting nucleic acids, reacts with RhoA to produce a RhoA thiol−cisplatin−thiol adduct, leading to inactivation of RhoA. Similarly, certain arsenic complexes (i.e., arsenate and arsenic trioxide) may inactivate RhoA by bridging the cysteine residues in the GXXXCGK(S/T)C motif. Thus, in addition to redox agents, platinated-chemotherapeutic agents and arsenic complexes may modulate the activity of GTPases containing the GXXXCGK(S/T)C motif (i.e., RhoA and RhoB).Keywords
This publication has 12 references indexed in Scilit:
- RHO GTPASES: Biochemistry and BiologyAnnual Review of Cell and Developmental Biology, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- The Ras superfamily at a glanceJournal of Cell Science, 2005
- The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapyCancer Biology & Therapy, 2005
- Molecular Basis for Rho GTPase Signaling SpecificityBreast Cancer Research and Treatment, 2004
- The Efficiency and Fidelity of Translesion Synthesis past Cisplatin and Oxaliplatin GpG Adducts by Human DNA Polymerase βJournal of Biological Chemistry, 2000
- Specificity of platinum–DNA adduct repairJournal of Inorganic Biochemistry, 1999
- Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPaseJournal of Biological Chemistry, 1998
- Crystal Structure of Human RhoA in a Dominantly Active Form Complexed with a GTP AnalogueJournal of Biological Chemistry, 1998
- Is Cisplatin a Human Carcinogen?JNCI: Journal of the National Cancer Institute, 1992